![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Active Filter(s):
Details:
The agreement covers exclusive commercialization rights to CRB-701, a novel clinical stage antibody drug conjugate (ADC) targeting Nectin-4, in the United States, Canada, the European Union (including the European Free Trade Area), the United Kingdom, and Australia.
Lead Product(s): Antibody-drug Conjugate
Therapeutic Area: Oncology Product Name: CRB-701
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Corbus Pharmaceuticals
Deal Size: $692.5 million Upfront Cash: $7.5 million
Deal Type: Licensing Agreement February 13, 2023